stockrowCogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) EV/FCF
As of 6 November 2026, Cogent Biosciences, Inc. (COGT) trades at a EV/FCF of −15.6×. Over the past ten years it has ranged from −22.1× (December 2025) to 5.7× (March 2021); the current reading is higher than 8% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2020 | 4.2× | 1,473.39% |
| FY2019 | 0.3× | — |
| FY2018 | −0.9× | — |
| FY2017 | −2.7× | — |
| FY2016 | −2.7× | — |
| FY2015 | −2.7× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2020 | −4.0× | — |
| Jun 2020 | 0.1× | (71.25%) |
| Mar 2020 | 0.3× | 30.64% |
| Dec 2019 | 0.3× | (62.64%) |
| 11 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| MANE Veradermics Incorporated compare | −38.8× |
| KOD Kodiak Sciences Inc. compare | −38.2× |
| PTCT PTC Therapeutics, Inc. compare | −23.9× |
| DNTH Dianthus Therapeutics, Inc. compare | −23.4× |
| SRRK Scholar Rock Holding Corporation compare | −19.6× |
| ERAS Erasca, Inc. compare | −16.6× |
| COGT Cogent Biosciences, Inc. | −15.6× |
| CRSP CRISPR Therapeutics AG compare | −8.3× |
| TVTX Travere Therapeutics, Inc. compare | 56.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement